Abbott Laboratories Nears Completion of Major Strategic Acquisition

Abbott Laboratories completes its strategic takeover of Exact Sciences, aiming to strengthen its diagnostics segment. The deal concludes after regulatory approval, with analysts maintaining buy ratings.

The healthcare giant Abbott Laboratories is on the verge of finalizing a significant strategic acquisition, following months of preparation. The official integration of Exact Sciences is scheduled for completion tomorrow, Monday. This move solidifies the corporation's standing in the diagnostics market and marks the successful conclusion of the regulatory review process.

Market Reaction and Analyst Outlook

Despite the strategic importance of the deal, the market's response has been muted. Shares closed on Friday at 91.40 euros, trading approximately 15 percent below their long-term 200-day moving average. Since the start of the year, the stock has declined by about 13.8 percent.

Market observers, however, view this acquisition as a crucial enhancement to Abbott's existing healthcare infrastructure. Analysts largely maintain their buy recommendations, with the consensus average price target standing at $139.48. The focus now shifts to the operational phase, which begins with the formal completion of the takeover set for March 23. Management's primary challenge will be the swift incorporation of the new business units into Abbott's established framework to realize the anticipated synergy effects in the diagnostics segment promptly.

Regulatory Hurdles Cleared

The final regulatory approval was granted last Thursday, removing the last obstacle to the merger. The two companies had initially agreed to the transaction in November 2025. Shareholders provided their approval in February of this year, leaving only the necessary regulatory consents for the acquisition of the company valued at nearly $19.8 billion.